AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01049607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Description: The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
Study NCT00781586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)
Description: One A Day Weight Smart Advanced 1 tablet at 1st visit
Study NCT00781586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine 100 mg 1 tablet at 1st visit
Study NCT00781586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet at 1st visit
Study NCT02363634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium threonate
Description: nutritional product
Study NCT03481998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT03481998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole or anastrozole or Fulvestrant
Description: Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study NCT03344055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision (ECV) second generation
Description: Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope
Study NCT03956706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
Study NCT05709080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family-professional collaboration practice model
Description: Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
Study NCT00407875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity Modulated External Beam Radiation Therapy
Study NCT00407875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated External Beam Radiation Therapy
Study NCT03040154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Video that is publicly available
Study NCT00628355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
Study NCT00628355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
Study NCT04580147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
Study NCT04580147 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
Study NCT00797121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage
Description: Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
Study NCT04144621 — intervention group
Intervention type: PROCEDURE
Intervention: ICSI
Description: Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
Study NCT03971721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wave 4.3
Description: The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
Study NCT04970667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol melitracen tablets
Description: Patients were treated with Flupentixol and melitracen tablets for 12 weeks
Study NCT03912584 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study NCT03912584 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TxE
Description: The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study NCT01321489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate 20mg Tablet Sublingual
Description: Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
Study NCT01321489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra ® 50mg tablet Coated
Description: Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
Study NCT03935516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: The use of plaster and/or fiberglass for casting of subject arm.
Study NCT01526356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study cream is applied nightly to the affected areas on the face.
Study NCT01526356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Study cream is applied nightly to the affected areas on the face. Low Dose
Study NCT01526356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Study cream is applied nightly to the affected areas on the face. High Dose
Study NCT01668368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: esophageal balloon
Description: esophageal pressure as a surrogate for pleural pressure
Study NCT01236391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 560 mg daily
Study NCT02056678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen, IV preparation
Study NCT02566005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
Study NCT00402233 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT03665818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance treatment
Description: mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
Study NCT02483767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Gonadotropin-Releasing Hormone Agonist
Study NCT02483767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Study NCT00670787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pill of losartan and hydrochlorothiazide
Description: Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Study NCT01769105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow
Description: Patients receive a single Lipiflow-treatment
Study NCT01769105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lid hygiene regime
Description: Patients receive verbal and written instruction to perform lid hygiene twice daily
Study NCT00105872 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Therapy
Study NCT03085784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
Study NCT02483767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Study NCT02158559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong Injection
Description: Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
Study NCT02158559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
Study NCT03148210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy using evidence-based guidelines for asthma or COPD
Description: The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
Study NCT03148210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation counselling by a qualified educator if currently smoking
Study NCT03148210 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation counselling by a qualified educator if currently smoking
Study NCT03148210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participant Education
Description: Standardized education for asthma or COPD disease
Study NCT02104037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Study NCT02556164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
Study NCT02556164 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
Study NCT02556164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-worn sensor technology
Description: Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
Study NCT03011125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole injection
Study NCT03011125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03219164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
Study NCT03219164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
Study NCT01005160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: CKD-501 0.5mg, metformin 1000mg
Study NCT01005160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, metformin 1000mg
Study NCT01608425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine consultations
Description: Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
Study NCT00500266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Study NCT04607395 — intervention group
Intervention type: RADIATION
Intervention: pre-operative radiograph
Description: Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio).
Study NCT01431287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination
Study NCT01431287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose or high dose
Study NCT02556164 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Body-worn sensor technology
Description: Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
Study NCT00938886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Daily 50 mg naltrexone
Study NCT00938886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched naltrexone placebo
Study NCT01431287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only
Study NCT01431287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT01431287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT00136864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Diagnostic Imaging
Description: Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
Study NCT01775748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Concord Grape Juice 12 oz per day
Description: Grape Juice 12 oz per day
Study NCT01775748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Grape Juice 12 oz per day
Description: Placebo Grape Juice 12 oz per day
Study NCT03733912 — intervention group
Intervention type: OTHER
Intervention: Phthalate metabolites measurement
Description: To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
Study NCT03089788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home-based test
Description: Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
Study NCT03089788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin test
Description: Skin Prick Tests will be performed with registered cat allergen extract.
Study NCT01622426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tolerance to a new aminoacid based formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
Study NCT01622426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid formula
Description: Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
Study NCT02967757 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
Study NCT02420834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypromellose 0.15%
Description: Tear supplement to be taken as required to relieve symptoms
Study NCT03055026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Tablets
Study NCT02420834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypromellose 0.4%
Description: Tear supplement to be taken as required to relieve symptoms
Study NCT04825353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic compbined guided PCNL
Description: patient undergo stone removal by ECIRS
Study NCT04825353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCNL
Description: patient undergo SPCNL
Study NCT03055026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT03148730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop group
Description: Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
Study NCT02285179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
Study NCT00222716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving counseling
Description: Telephone nurse counseling behavioral intervention focused on problem solving.
Study NCT00300430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and rosuvastatin calcium
Description: ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
Study NCT00300430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and atorvastatin calcium
Description: ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
Study NCT00300430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and simvastatin
Description: ABT-335 135 mg plus simvastatin daily, 52 weeks